$HQY

Wellborn Gayle Furgurson sold $220K of HQY

Wellborn Gayle Furgurson sold 2,439 shares of HEALTHEQUITY, INC. (HQY) at $90.00 ($0.22M total) on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wellborn Gayle Furgurson
Published Jun 1, 2026, 10:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$HQY
Neutral
medium confidence
Mentioned
$HQY
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HQYNeutralLow
01

Why it matters

The disclosure may slightly influence sentiment, but it is unlikely to change valuation materially absent other company-specific news.

02

Market read

Traders may note the insider sale for sentiment tracking, but the 10b5-1 designation reduces the likelihood of a meaningful price reaction.

03

What to watch

The filing doesn’t reveal intent beyond the plan; without a pattern of repeated sales or size relative to holdings, signal strength is limited.

Relevance 6/10Novelty 6/10Timing: Filed today; sale occurred 2026-05-28 (10b5-1 plan).

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by a director with a stated 10b5-1 pre-arranged plan.

Company-level read

Ticker impact

$HQYNeutralMedium confidence
Context

Director Wellborn Gayle Furgurson sold 2,439 shares in an open-market transaction at $90.00/share, disclosed via SEC Form 4.

Expected impact

Likely limited near-term impact; any effect should be small versus broader fundamentals.

Evidence & confidence

This is an ownership-change disclosure without accompanying operational or financial catalyst; 10b5-1 pre-arrangement typically dampens signaling value.

Market effects

Minimal; single-company insider transaction with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale was executed under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • HEALTHEQUITY, INC.

    HQY, subject of the insider transaction disclosure.

  • Wellborn Gayle Furgurson

    Director who sold shares under an open-market transaction and 10b5-1 plan.

Related articles

$HQYMed

HealthEquity rating upgraded by Moody’s on strong cash flow

Moody’s upgraded HealthEquity, Inc. (NASDAQ:HQY) corporate family rating to Ba2 from Ba3 and raised its probability of default rating to Ba2-PD from Ba3-PD. It also upgraded $600 million senior unsecured notes to Ba3 from B1, with outlook changed to stable. Moody’s cited stronger operating cash flow and BenefitWallet integration, plus improved leverage and liquidity.

$HQYMedAI 9/10

HealthEquity Q1 2027 Earnings Call: Complete Transcript - HealthEquity (NASDAQ: HQY)

HealthEquity reported fiscal 2027 first-quarter results, citing 7% year-over-year revenue growth and a record adjusted EBITDA margin of 46%, according to the company. It raised guidance to $1.41–$1.42B revenue and $625–$633M adjusted EBITDA. The firm said it expanded digital engagement and Marketplace, used AI for efficiency, saw HSA assets +19% and new HSA sales +15%, and increased its share repurchase authorization by $1B.